192 related articles for article (PubMed ID: 1661632)
1. Serum concentrations of immunoglobulins and of antibody isotypes in bone marrow transplant recipients treated with high doses of polyspecific immunoglobulin or with cytomegalovirus hyperimmune globulin.
Gratwohl A; Doran JE; Bachmann P; Scherz R; Späth P; Baumgartner C; Perret B; Berger C; Nissen C; Tichelli A
Bone Marrow Transplant; 1991 Oct; 8(4):275-82. PubMed ID: 1661632
[TBL] [Abstract][Full Text] [Related]
2. [Serum immunoglobulin concentrations in patients following bone marrow transplantation and preventive administration of high-dose nonspecific or normal-dose CMV-specific immunoglobulin].
Berger C; Gratwohl A; Doran JE; Scherz R; Baumgartner C; Morell A; Bachmann B; Spaeth PJ; Tichelli A; Speck B
Beitr Infusionsther; 1989; 24():112-21. PubMed ID: 2481528
[TBL] [Abstract][Full Text] [Related]
3. Kinetics of cytomegalovirus IgG antibody following infusion of a hyperimmune globulin preparation in allogeneic marrow transplant recipients.
Reusser P; Osterwalder B; Gratama JW; The TH; Gratwohl A; Speck B
Bone Marrow Transplant; 1989 May; 4(3):267-72. PubMed ID: 2543469
[TBL] [Abstract][Full Text] [Related]
4. Kinetics of anti-CMV antibodies after administration of intravenous immunoglobulins to bone marrow transplant recipients.
Bosi A; De Majo E; Guidi S; Parri F; Saccardi R; Vannucchi AM; Fanci R; Ferrini PR
Haematologica; 1990; 75(2):109-12. PubMed ID: 2162799
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of cytomegalovirus specific IgG antibody following intravenous immunoglobulin in bone marrow transplant patients.
Rand KH; Houck H; Ganju A; Babington RG; Elfenbein GJ
Bone Marrow Transplant; 1989 Nov; 4(6):679-83. PubMed ID: 2555005
[TBL] [Abstract][Full Text] [Related]
6. No prevention of cytomegalovirus infection by anti-cytomegalovirus hyperimmune globulin in seronegative bone marrow transplant recipients. The Nordic BMT Group.
Ruutu T; Ljungman P; Brinch L; Lenhoff S; Lönnqvist B; Ringdén O; Ruutu P; Volin L; Albrechtsen D; Sallerfors B; Ebeling F; Myllylä G
Bone Marrow Transplant; 1997 Feb; 19(3):233-6. PubMed ID: 9028551
[TBL] [Abstract][Full Text] [Related]
7. Some but not all benefits of intravenous immunoglobulin therapy after marrow transplantation appear to correlate with IgG trough levels.
Cottler-Fox M; Lynch M; Pickle LW; Cahill R; Spitzer TR; Deeg HJ
Bone Marrow Transplant; 1991 Jul; 8(1):27-33. PubMed ID: 1655138
[TBL] [Abstract][Full Text] [Related]
8. Salivary immunoglobulins in recipients of bone marrow grafts. III. A longitudinal follow-up of CMV specific antibodies.
Chaushu G; Chaushu S; Slavin S; Or R; Garfunkel AA; Yefenof E
Bone Marrow Transplant; 1996 Feb; 17(2):237-41. PubMed ID: 8640173
[TBL] [Abstract][Full Text] [Related]
9. Does high-dose intravenous immune globulin treatment after bone marrow transplantation increase mortality in veno-occlusive disease of the liver?
Klaesson S; Ringdén O; Ljungman P; Aschan J; Hägglund H; Winiarski J
Transplantation; 1995 Dec; 60(11):1225-30. PubMed ID: 8525515
[TBL] [Abstract][Full Text] [Related]
10. IgG subclass antibodies to human cytomegalovirus (CMV) in normal human plasma samples and immune globulins and their neutralizing activities.
Gupta CK; Leszczynski J; Gupta RK; Siber GR
Biologicals; 1996 Jun; 24(2):117-24. PubMed ID: 8889058
[TBL] [Abstract][Full Text] [Related]
11. Immune monitoring of anti cytomegalovirus antibodies and risk of cytomegalovirus disease in heart transplantation.
Sarmiento E; Lanio N; Gallego A; Rodriguez-Molina J; Navarro J; Fernandez-Yañez J; Palomo J; Rodríguez-Hernández C; Ruiz M; Alonso R; Fernandez-Cruz E; Carbone J
Int Immunopharmacol; 2009 Jun; 9(6):649-52. PubMed ID: 18940269
[TBL] [Abstract][Full Text] [Related]
12. A randomized trial of high dose polyvalent intravenous immunoglobulin (HDIgG) vs. Cytomegalovirus (CMV) hyperimmune IgG in allogeneic hemopoietic stem cell transplants (HSCT).
Zikos P; Van Lint MT; Lamparelli T; Gualandi F; Occhini D; Mordini N; Berisso G; Bregante S; Bacigalupo A
Haematologica; 1998 Feb; 83(2):132-7. PubMed ID: 9549924
[TBL] [Abstract][Full Text] [Related]
13. Prophylaxis of CMV infection in bone marrow transplant recipients by hyperimmune CMV gamma-globulin.
Condie RM; O'Reilly RJ
Dev Biol Stand; 1982; 52():501-13. PubMed ID: 6299859
[TBL] [Abstract][Full Text] [Related]
14. [Specific anti-cytomegalovirus immunoglobulins in the prevention of cytomegalovirus infections in bone marrow allografts].
Huart JJ; Baume D; Jouet JP
Ann Med Interne (Paris); 1987; 138(5):372-4. PubMed ID: 2823667
[TBL] [Abstract][Full Text] [Related]
15. [Clinical and biological evaluation of the preventive role of anti-cytomegalovirus specific immunoglobulins in bone marrow grafts. Randomized study of 60 patients].
Bordigoni P; Janot C; Aymard JP; Witz F; Bené MC; Legras B; Schoonemann F; Olive D; Streiff F
Nouv Rev Fr Hematol (1978); 1987; 29(5):289-93. PubMed ID: 2830588
[TBL] [Abstract][Full Text] [Related]
16. CMV infections in bone marrow transplanted patients--evaluation of prophylaxis with Cytotect (CMV hyperimmuneglobulin).
Zintl F; Färber I; Hermann J; Fuchs D; Prager J; Wutzler P
Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(3-4):557-64. PubMed ID: 2480308
[TBL] [Abstract][Full Text] [Related]
17. [Prophylactic and therapeutic use of immunoglobulins in patients with bone marrow transplantation].
Timár L; Kriván G; Kövesdi R
Orv Hetil; 1994 Feb; 135(8):405-8. PubMed ID: 8139843
[TBL] [Abstract][Full Text] [Related]
18. Cytomegalovirus neutralization by hyperimmune and standard intravenous immunoglobulin preparations.
Planitzer CB; Saemann MD; Gajek H; Farcet MR; Kreil TR
Transplantation; 2011 Aug; 92(3):267-70. PubMed ID: 21659947
[TBL] [Abstract][Full Text] [Related]
19. Cytomegalovirus prophylaxis with intravenous polyvalent immunoglobulin in high-risk renal transplant recipients.
Leroy F; Sechet A; Abou Ayache R; Thierry A; Belmouaz S; Desport E; Bauwens M; Bridoux F; Touchard G
Transplant Proc; 2006 Sep; 38(7):2324-6. PubMed ID: 16980080
[TBL] [Abstract][Full Text] [Related]
20. CMV antigenemia (the lower matrix protein PP65), a marker for the guidance of antiviral therapy in cytomegalovirus disease after orthotopic heart transplantation.
Iberer F; Tscheliessnigg KH; Halwachs G; Auer T; Wasler A; Petutschnigg B; Müller H; Freigassner M; Allmayr T; Hipmair G
Wien Klin Wochenschr; 1995; 107(23):718-22. PubMed ID: 8560893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
